Impact of Risk-Based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the childhood cancer survivor study

CONCLUSION: Survivors of high-risk disease treated in the early days of risk stratification carry a markedly elevated burden of late recurrence, SMN, and organ-related multi-morbidity, while survivors of low/intermediate-risk disease have a modest risk of late adverse outcomes.PMID:38460547 | DOI:10.1093/jnci/djae062

Source: Cancer Control - March 9, 2024 Category: Cancer & Oncology Authors: Danielle Novetsky Friedman Pamela J Goodman Wendy M Leisenring Lisa R Diller Susan L Cohn Rebecca M Howell Susan A Smith Emily S Tonorezos Suzanne L Wolden Joseph P Neglia Kirsten K Ness Todd M Gibson Paul C Nathan Lucie M Turcotte Brent R Weil Leslie L R Source Type: research